Measles virus: Improving natural oncolytic properties by genetic engineering

Christoph Springfeld, Adele Fielding, Kah-Whye Peng, Evanthia Galanis, Stephen J Russell, Roberto Cattaneo

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Measles is a highly contagious disease with a characteristic erythematous, nonpruritic, maculopapular rash that is preceded by an unspecific prodromal illness of malaise, cough, coryza, and fever [1,2]. Although an effective live vaccine has been available for more than 30years, measles is still a significant cause of morbidity and mortality in countries with poor or no vaccination coverage. Thirty to forty million cases of measles, resulting in 777,000 deaths, have been estimated for the year 2000 [3]. Mortality is associated with extreme ages, underlying illness, low socioeconomic status, lack of access to medical care, and malnutrition. Fatalities can be caused by secondary infections such as bacterial pneumonia, which are facilitated by an immunosuppression typical for measles. About one in 1000 children develops postinfectious encephalitis that is fatal in about 10% of the patients and frequently leads to sequelae in the surviving patients. An extremely rare (1 in 105 infections) fatal complication of measles, subacute sclerosing panencephalitis, can occur several years after wildtype measles virus (MV) infection and is caused by a persisting brain infection with defective virus mutants [4].

Original languageEnglish (US)
Title of host publicationViral Therapy of Human Cancers
PublisherCRC Press
Pages459-480
Number of pages22
ISBN (Electronic)9781420030402
ISBN (Print)9780824759131
StatePublished - Jan 1 2004

Fingerprint

Measles virus
Genetic Engineering
Measles
Subacute Sclerosing Panencephalitis
Defective Viruses
Bacterial Pneumonia
Mortality
Virus Diseases
Encephalitis
Infection
Exanthema
Coinfection
Cough
Social Class
Malnutrition
Immunosuppression
Vaccination
Fever
Vaccines
Morbidity

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Springfeld, C., Fielding, A., Peng, K-W., Galanis, E., Russell, S. J., & Cattaneo, R. (2004). Measles virus: Improving natural oncolytic properties by genetic engineering. In Viral Therapy of Human Cancers (pp. 459-480). CRC Press.

Measles virus : Improving natural oncolytic properties by genetic engineering. / Springfeld, Christoph; Fielding, Adele; Peng, Kah-Whye; Galanis, Evanthia; Russell, Stephen J; Cattaneo, Roberto.

Viral Therapy of Human Cancers. CRC Press, 2004. p. 459-480.

Research output: Chapter in Book/Report/Conference proceedingChapter

Springfeld, C, Fielding, A, Peng, K-W, Galanis, E, Russell, SJ & Cattaneo, R 2004, Measles virus: Improving natural oncolytic properties by genetic engineering. in Viral Therapy of Human Cancers. CRC Press, pp. 459-480.
Springfeld C, Fielding A, Peng K-W, Galanis E, Russell SJ, Cattaneo R. Measles virus: Improving natural oncolytic properties by genetic engineering. In Viral Therapy of Human Cancers. CRC Press. 2004. p. 459-480
Springfeld, Christoph ; Fielding, Adele ; Peng, Kah-Whye ; Galanis, Evanthia ; Russell, Stephen J ; Cattaneo, Roberto. / Measles virus : Improving natural oncolytic properties by genetic engineering. Viral Therapy of Human Cancers. CRC Press, 2004. pp. 459-480
@inbook{12214043572f4f8ea5f5675ee876030f,
title = "Measles virus: Improving natural oncolytic properties by genetic engineering",
abstract = "Measles is a highly contagious disease with a characteristic erythematous, nonpruritic, maculopapular rash that is preceded by an unspecific prodromal illness of malaise, cough, coryza, and fever [1,2]. Although an effective live vaccine has been available for more than 30years, measles is still a significant cause of morbidity and mortality in countries with poor or no vaccination coverage. Thirty to forty million cases of measles, resulting in 777,000 deaths, have been estimated for the year 2000 [3]. Mortality is associated with extreme ages, underlying illness, low socioeconomic status, lack of access to medical care, and malnutrition. Fatalities can be caused by secondary infections such as bacterial pneumonia, which are facilitated by an immunosuppression typical for measles. About one in 1000 children develops postinfectious encephalitis that is fatal in about 10{\%} of the patients and frequently leads to sequelae in the surviving patients. An extremely rare (1 in 105 infections) fatal complication of measles, subacute sclerosing panencephalitis, can occur several years after wildtype measles virus (MV) infection and is caused by a persisting brain infection with defective virus mutants [4].",
author = "Christoph Springfeld and Adele Fielding and Kah-Whye Peng and Evanthia Galanis and Russell, {Stephen J} and Roberto Cattaneo",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824759131",
pages = "459--480",
booktitle = "Viral Therapy of Human Cancers",
publisher = "CRC Press",

}

TY - CHAP

T1 - Measles virus

T2 - Improving natural oncolytic properties by genetic engineering

AU - Springfeld, Christoph

AU - Fielding, Adele

AU - Peng, Kah-Whye

AU - Galanis, Evanthia

AU - Russell, Stephen J

AU - Cattaneo, Roberto

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Measles is a highly contagious disease with a characteristic erythematous, nonpruritic, maculopapular rash that is preceded by an unspecific prodromal illness of malaise, cough, coryza, and fever [1,2]. Although an effective live vaccine has been available for more than 30years, measles is still a significant cause of morbidity and mortality in countries with poor or no vaccination coverage. Thirty to forty million cases of measles, resulting in 777,000 deaths, have been estimated for the year 2000 [3]. Mortality is associated with extreme ages, underlying illness, low socioeconomic status, lack of access to medical care, and malnutrition. Fatalities can be caused by secondary infections such as bacterial pneumonia, which are facilitated by an immunosuppression typical for measles. About one in 1000 children develops postinfectious encephalitis that is fatal in about 10% of the patients and frequently leads to sequelae in the surviving patients. An extremely rare (1 in 105 infections) fatal complication of measles, subacute sclerosing panencephalitis, can occur several years after wildtype measles virus (MV) infection and is caused by a persisting brain infection with defective virus mutants [4].

AB - Measles is a highly contagious disease with a characteristic erythematous, nonpruritic, maculopapular rash that is preceded by an unspecific prodromal illness of malaise, cough, coryza, and fever [1,2]. Although an effective live vaccine has been available for more than 30years, measles is still a significant cause of morbidity and mortality in countries with poor or no vaccination coverage. Thirty to forty million cases of measles, resulting in 777,000 deaths, have been estimated for the year 2000 [3]. Mortality is associated with extreme ages, underlying illness, low socioeconomic status, lack of access to medical care, and malnutrition. Fatalities can be caused by secondary infections such as bacterial pneumonia, which are facilitated by an immunosuppression typical for measles. About one in 1000 children develops postinfectious encephalitis that is fatal in about 10% of the patients and frequently leads to sequelae in the surviving patients. An extremely rare (1 in 105 infections) fatal complication of measles, subacute sclerosing panencephalitis, can occur several years after wildtype measles virus (MV) infection and is caused by a persisting brain infection with defective virus mutants [4].

UR - http://www.scopus.com/inward/record.url?scp=85058319483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058319483&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85058319483

SN - 9780824759131

SP - 459

EP - 480

BT - Viral Therapy of Human Cancers

PB - CRC Press

ER -